{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-043281","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.315606+00:00","generated_at":"2026-05-30T12:12:35.774630+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"USANA Q3 net sales $200M (-6% YoY); cuts FY2024 EPS guidance to $2.45","bullets":["Q3 diluted EPS $0.56 vs $0.59 YoY; net sales down 6% to $200M.","Active customers fell 3% YoY to 452,000; Greater China customers rose 6% but sales -4%.","FY2024 outlook narrowed: net sales ~$850M (from $850-880M), EPS $2.45 (from $2.40-2.55).","Balance sheet: $365M cash, debt-free; no shares repurchased in Q3.","Regional weakness: North Asia -15%, Americas & Europe -7% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-043281","json":"https://secwatch.observer/filing/0001628280-24-043281.json","markdown":"https://secwatch.observer/filing/0001628280-24-043281.md","text":"https://secwatch.observer/filing/0001628280-24-043281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000162828024043281/0001628280-24-043281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000162828024043281/usna-20241022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:12:35.774630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}